You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,709,694


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,709,694 protect, and when does it expire?

Patent 10,709,694 protects XIFAXAN and is included in one NDA.

This patent has fifty-six patent family members in twenty-one countries.

Summary for Patent: 10,709,694
Title:Methods of treating hepatic encephalopathy
Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.
Inventor(s): Forbes; William (Raleigh, NC)
Assignee: Salix Pharmaceuticals, Inc. (Bridgewater, NJ)
Application Number:16/414,018
Patent Claim Types:
see list of patent claims
Use; Delivery;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,709,694

Introduction

United States Patent 10,709,694, titled "Methods of treating hepatic encephalopathy," is a significant patent that addresses a critical medical condition. Here, we will delve into the details of its scope, claims, and the broader patent landscape it operates within.

Background of Hepatic Encephalopathy

Hepatic encephalopathy is a neurological disorder caused by liver disease, leading to cognitive, psychiatric, and motor disturbances. The treatment of this condition is complex and has been the subject of extensive medical research.

Patent Overview

The patent in question, US10709694B2, focuses on the use of gastrointestinal-specific antibiotics as a treatment method for hepatic encephalopathy. Here are the key aspects:

Inventive Concept

The patent describes the use of antibiotics that are specifically targeted at the gastrointestinal tract to reduce the production of ammonia and other neurotoxins that contribute to hepatic encephalopathy. This approach is innovative because it targets the root cause of the condition at the gut level[1].

Claims

The patent includes several claims that define the scope of the invention. These claims typically cover:

  • The specific antibiotics used (e.g., rifaximin).
  • The method of administration.
  • The dosage and treatment regimen.
  • The patient population (e.g., those with liver disease).

Scope of the Patent

The scope of the patent is defined by its claims, which are the legally binding descriptions of what the patent covers.

Independent and Dependent Claims

The patent includes both independent and dependent claims. Independent claims stand alone and define the invention broadly, while dependent claims build upon the independent claims and provide more specific details. For example, an independent claim might cover the use of rifaximin to treat hepatic encephalopathy, while a dependent claim might specify the dosage and frequency of administration[1].

Claim Language and Scope

The language used in the claims is crucial as it determines the breadth of protection. Narrower claims may be more easily enforceable but offer less protection, while broader claims may face more challenges during the examination process but offer wider protection if granted[3].

Examination and Approval Process

The examination process for this patent would have involved a thorough review by the United States Patent and Trademark Office (USPTO).

Prior Art and Novelty

The patent office would have evaluated the novelty and non-obviousness of the invention by comparing it to prior art. This involves ensuring that the treatment method is not already known or obvious to those skilled in the field[5].

Written Description and Enablement

The patent application must also meet the requirements of written description and enablement, meaning it must clearly describe the invention and provide enough detail for someone skilled in the field to replicate it[5].

Patent Landscape

The patent landscape for treatments of hepatic encephalopathy is dynamic and involves various approaches.

Competing Patents and Technologies

Other patents may cover different treatment methods, such as dietary interventions, other pharmaceuticals, or even surgical procedures. The landscape is competitive, with multiple stakeholders seeking to develop effective treatments[1].

Trends and Innovations

Recent trends in treating hepatic encephalopathy include a focus on gut-liver axis therapies, which align with the approach described in US10709694B2. Innovations in this area are driven by the need for more effective and targeted treatments[1].

Impact on Medical Practice

The approval of this patent can significantly impact medical practice by providing a new treatment option for patients with hepatic encephalopathy.

Clinical Trials and Evidence

The patent is likely supported by clinical trials and other evidence demonstrating the efficacy and safety of the treatment. This evidence is crucial for regulatory approval and adoption by healthcare providers[1].

Patient Outcomes

The ultimate measure of the patent's impact is the improvement in patient outcomes. By reducing ammonia levels and other neurotoxins, this treatment can potentially improve cognitive function, quality of life, and survival rates for patients with hepatic encephalopathy.

Economic and Commercial Implications

The economic and commercial implications of this patent are substantial.

Market Potential

The market for treatments of hepatic encephalopathy is significant, given the prevalence of liver diseases. A patented treatment can provide a competitive edge and generate substantial revenue for the patent holder[1].

Licensing and Collaboration

The patent holder may choose to license the technology to other pharmaceutical companies or collaborate on further research and development. This can expand the reach of the treatment and accelerate innovation in the field.

Challenges and Controversies

Like any patent, US10709694B2 may face challenges and controversies.

Patent Litigation

The patent could be subject to litigation over issues such as infringement, validity, or scope. Such disputes can be costly and time-consuming but are a common aspect of the patent landscape[2].

Regulatory Approval

Beyond patent approval, the treatment must also gain regulatory approval from bodies like the FDA. This process involves rigorous testing and evaluation to ensure safety and efficacy.

Key Takeaways

  • Innovative Treatment: The patent introduces a novel approach to treating hepatic encephalopathy using gastrointestinal-specific antibiotics.
  • Scope and Claims: The patent's scope is defined by its claims, which specify the antibiotics, method of administration, and patient population.
  • Examination Process: The patent underwent a thorough examination by the USPTO to ensure novelty, non-obviousness, written description, and enablement.
  • Impact on Medical Practice: The patent can significantly impact medical practice by providing a new treatment option with potential to improve patient outcomes.
  • Economic Implications: The patent has substantial economic and commercial implications, including market potential and licensing opportunities.

FAQs

Q: What is the main focus of US10709694B2? A: The main focus is on the use of gastrointestinal-specific antibiotics to treat hepatic encephalopathy.

Q: What are the key claims in the patent? A: The key claims cover the specific antibiotics used, the method of administration, dosage, and treatment regimen.

Q: How does the patent impact medical practice? A: It provides a new treatment option that can improve patient outcomes by reducing ammonia levels and other neurotoxins.

Q: What are the economic implications of this patent? A: The patent has significant market potential and can generate substantial revenue for the patent holder through licensing and collaboration.

Q: What challenges might the patent face? A: The patent could face challenges such as patent litigation, regulatory approval issues, and competition from other treatments.

Citations

  1. US10709694B2 - Methods of treating hepatic encephalopathy - Google Patents
  2. Hyatt v. Hirshfeld - Court of Appeals for the Federal Circuit
  3. Patent Claims and Patent Scope - SSRN
  4. hfto-2021-patent-analysis.pdf - Department of Energy
  5. Determining Inventorship for US Patent Applications - Oregon State University

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,709,694

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 RX Yes Yes ⤷  Subscribe ⤷  Subscribe REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,709,694

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009298389 ⤷  Subscribe
Australia 2010260089 ⤷  Subscribe
Australia 2010271070 ⤷  Subscribe
Brazil PI0920465 ⤷  Subscribe
Brazil PI1010028 ⤷  Subscribe
Canada 2739436 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.